COSCIENS Biopharma Inc. (CSCIF) earnings per share
Annual history
Fiscal years 2017 – 2025
USD / SHARE 10 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-12-31 | -$3.27 | 2026-03-25 |
| FY 2024 | 2024-12-31 | -$5.93 | 2025-04-09 |
| FY 2023 | 2023-12-31 | -$1.89 | 2024-03-27 |
| FY 2022 | 2022-12-31 | $1.86 | 2023-03-23 |
| FY 2021 | 2021-12-31 | -$1.82 | 2022-03-29 |
| FY 2020 | 2020-12-31 | -$12.44 | 2021-03-25 |
| FY 2019 | 2019-12-31 | -$35.00 | 2020-03-31 |
| FY 2018 | 2018-12-31 | $24.00 | 2019-04-01 |
| FY 2017 | 2017-12-31 | -$112.00 | 2018-03-28 |
| FY 2017 | 2016-12-31 | -$241.00 | 2018-03-28 |
Quarterly history
Fiscal years 2018 – 2025
USD / SHARE 31 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | -$0.68 | 2026-03-25 |
| Q3 2025 | 2025-09-30 | -$0.57 | 2025-11-12 |
| Q2 2025 | 2025-06-30 | -$0.85 | 2025-08-14 |
| Q1 2025 | 2025-03-31 | -$1.16 | 2025-05-13 |
| Q4 2024 | 2024-12-31 | -$2.35 | 2025-04-09 |
| Q3 2024 | 2024-09-30 | -$1.85 | 2024-11-12 |
| Q2 2024 | 2024-06-30 | -$0.64 | 2024-08-13 |
| Q1 2024 | 2024-03-31 | -$0.76 | 2024-05-16 |
| Q4 2023 | 2023-12-31 | -$0.85 | 2024-03-27 |
| Q3 2023 | 2023-09-30 | -$0.42 | 2023-11-09 |
| Q2 2023 | 2023-06-30 | -$0.47 | 2023-08-09 |
| Q1 2023 | 2023-03-31 | -$3.51 | 2023-05-09 |
| Q4 2022 | 2022-12-31 | $10.34 | 2023-03-23 |
| Q3 2022 | 2022-09-30 | -$2.80 | 2022-11-03 |
| Q2 2022 | 2022-06-30 | -$3.48 | 2022-08-04 |
| Q1 2022 | 2022-03-31 | -$2.00 | 2022-05-11 |
| Q4 2021 | 2021-12-31 | $3.02 | 2022-03-29 |
| Q3 2021 | 2021-09-30 | $1.60 | 2021-11-04 |
| Q2 2021 | 2021-06-30 | -$1.72 | 2021-08-05 |
| Q1 2021 | 2021-03-31 | -$2.00 | 2021-05-05 |
| Q4 2020 | 2020-12-31 | -$1.44 | 2021-03-25 |
| Q3 2020 | 2020-09-30 | -$2.00 | 2020-11-05 |
| Q2 2020 | 2020-06-30 | -$15.00 | 2020-08-06 |
| Q1 2020 | 2020-03-31 | $4.00 | 2020-05-06 |
| Q4 2019 | 2019-12-31 | -$4.00 | 2020-03-31 |
| Q3 2019 | 2019-09-30 | -$2.00 | 2019-11-07 |
| Q2 2019 | 2019-06-30 | $1.00 | 2019-08-13 |
| Q1 2020 | 2019-03-31 | -$30.00 | 2020-05-06 |
| Q4 2018 | 2018-12-31 | -$32.00 | 2019-04-01 |
| Q3 2019 | 2018-09-30 | -$15.00 | 2019-11-07 |
| Q2 2019 | 2018-06-30 | -$16.00 | 2019-08-13 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer. Per-share values are split-adjusted to the current share count (4 split s since 2012).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
CSCIF CIK 0001113423 Source: EDGAR filings · all facts